PD-L1.
File(s)
Accepted version
Author(s)
Kythreotou, Anthousa
Siddique, Abdul
Mauri, Francesco A
Bower, Mark
Pinato, David J
Type
Journal Article
Abstract
Programmed death ligand 1 (PD-L1) is the principal ligand of programmed death 1 (PD-1), a coinhibitory receptor that can be constitutively expressed or induced in myeloid, lymphoid, normal epithelial cells and in cancer. Under physiological conditions, the PD-1/PD-L1 interaction is essential in the development of immune tolerance preventing excessive immune cell activity that can lead to tissue destruction and autoimmunity. PD-L1 expression is an immune evasion mechanism exploited by various malignancies and is generally associated with poorer prognosis. PD-L1 expression is also suggested as a predictive biomarker of response to anti-PD-1/PD-L1 therapies; however, contradictory evidence exists as to its role across histotypes. Over the years, anti-PD-1/PD-L1 agents have gained momentum as novel anticancer therapeutics, by inducing durable tumour regression in numerous malignancies including metastatic lung cancer, melanoma and many others. In this review, we discuss the immunobiology of PD-L1, with a particular focus on its clinical significance in malignancy.
Date Issued
2017-11-02
Date Acceptance
2017-10-19
Citation
Journal of Clinical Pathology, 2017, 71, pp.189-194
ISSN
1472-4146
Publisher
BMJ Publishing Group
Start Page
189
End Page
194
Journal / Book Title
Journal of Clinical Pathology
Volume
71
Copyright Statement
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Sponsor
ViiV Healthcare UK Limited
Identifier
PII: jclinpath-2017-204853
Grant Number
N/A
Subjects
cancer
immunology
oncogenes
Publication Status
Published